Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849744478700568576 |
|---|---|
| author | Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li |
| author_facet | Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li |
| author_sort | Miao Wang |
| collection | DOAJ |
| description | Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and explore the effect of clinical characteristics on it. Materials and Methods From October 2017 to April 2020, a total of 90 patients from Capital Medical University Affiliated Beijing Friendship Hospital were enrolled. Results At a median follow‐up of 10.55 months, objective response was observed in 23 patients and the objective response rate was 25.6%. The median progression‐free survival (PFS) was 5.5 months (95% confidence interval [CI], 3.69–7.37). The 6m‐PFS was 45.8% and 12m‐PFS was 25.1%. The median overall survival (OS) was 16.9 months (95% CI, not reached [NR]‐NR). The 12m‐OS was 58.1% and 18m‐OS was 48.1%. Conclusion The efficacy of PD‐1/PD‐L1 inhibitors in the treatment of advanced solid tumors was comparable to previous studies. ECOG performance status, smoking status, liver metastasis, neutrophil‐to‐lymphocyte ratio were independently correlated with PFS while liver metastasis and lactate dehydrogenase level were independently correlated with OS. |
| format | Article |
| id | doaj-art-7e67fd62bbea405ca3ca1c424f2c1796 |
| institution | DOAJ |
| issn | 2050-4527 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-7e67fd62bbea405ca3ca1c424f2c17962025-08-20T03:15:35ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941584159510.1002/iid3.511Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumorsMiao Wang0Hongchao Zhen1Xiaoyue Jiang2Yuting Lu3Yuhan Wei4Jiangtao Jin5Qin Li6Department of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaDepartment of Intervention Therapy Zezhou People's Hospital Jincheng ChinaDepartment of Oncology, Beijing Friendship Hospital Capital Medical University Beijing ChinaAbstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and explore the effect of clinical characteristics on it. Materials and Methods From October 2017 to April 2020, a total of 90 patients from Capital Medical University Affiliated Beijing Friendship Hospital were enrolled. Results At a median follow‐up of 10.55 months, objective response was observed in 23 patients and the objective response rate was 25.6%. The median progression‐free survival (PFS) was 5.5 months (95% confidence interval [CI], 3.69–7.37). The 6m‐PFS was 45.8% and 12m‐PFS was 25.1%. The median overall survival (OS) was 16.9 months (95% CI, not reached [NR]‐NR). The 12m‐OS was 58.1% and 18m‐OS was 48.1%. Conclusion The efficacy of PD‐1/PD‐L1 inhibitors in the treatment of advanced solid tumors was comparable to previous studies. ECOG performance status, smoking status, liver metastasis, neutrophil‐to‐lymphocyte ratio were independently correlated with PFS while liver metastasis and lactate dehydrogenase level were independently correlated with OS.https://doi.org/10.1002/iid3.511advanced solid tumorclinical efficacyefficacy predictionimmunotherapyPD‐1/PD‐L1 inhibitor |
| spellingShingle | Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors Immunity, Inflammation and Disease advanced solid tumor clinical efficacy efficacy prediction immunotherapy PD‐1/PD‐L1 inhibitor |
| title | Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors |
| title_full | Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors |
| title_fullStr | Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors |
| title_full_unstemmed | Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors |
| title_short | Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors |
| title_sort | clinical observation of the efficacy of pd 1 pd l1 inhibitors in the treatment of patients with advanced solid tumors |
| topic | advanced solid tumor clinical efficacy efficacy prediction immunotherapy PD‐1/PD‐L1 inhibitor |
| url | https://doi.org/10.1002/iid3.511 |
| work_keys_str_mv | AT miaowang clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT hongchaozhen clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT xiaoyuejiang clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT yutinglu clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT yuhanwei clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT jiangtaojin clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT qinli clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors |